According to the pathogenesis of biological iron metabolism disorder and monoamine oxidase B (MAO-B) overexpression in the brain of AD patients, a series of dual-target anti-AD compounds were designed and synthesized by our research team in the early stage, and the candidate compound with the best activity XYY-CP1106 was obtained [18]. Here, MAOB is linked to Alzheimer disease.